
Feb 18 (Reuters) - Biogen Inc BIIB.O:
BIOGEN AND STOKE THERAPEUTICS ENTER INTO COLLABORATION TO DEVELOP AND COMMERCIALIZE ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME, A RARE GENETIC EPILEPSY ASSOCIATED WITH REFRACTORY SEIZURES AND NEURODEVELOPMENTAL IMPAIRMENTS
BIOGEN INC - PHASE 3 STUDY OF ZOREVUNERSEN TO INITIATE IN Q2 2025
BIOGEN INC - STOKE RETAINS EXCLUSIVE RIGHTS FOR ZOREVUNERSEN IN US, CANADA, MEXICO; BIOGEN GETS REST OF WORLD
Source text: ID:nBwbh3DmPa
Further company coverage: BIIB.O